ZHCL.F Share Price Performance
US$0.10
0.09 (890.10%)
Price US$0.10
Share PriceUS$0.10
Zenith Capital Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ZHCL.F Community Narratives
There are no narratives available yet.
Recent ZHCL.F News & Updates
Zenith Capital Corp. Key Details
Last Reported Earnings
Jul 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.044
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,406.20%
- Debt/Equity Ratio
- -67.5%
Zenith Capital Corp. Competitors
Snowflake Analysis
About ZHCL.F
- Founded
- 2013
- Employees
- n/a
- CEO
- WebsiteView website
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Canadian Market Performance
- 7 Days: 0.9%
- 3 Months: 10.5%
- 1 Year: 22.5%
- Year to Date: 20.0%
The Healthcare sector gained 5.0% while the market remained flat over the last week. As for the longer term, the market has risen 23% in the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›